Liposomal Targeting of Bcl-2 Antisense Oligonucleotides with Enhanced Stability into Human Myeloma Cell Lines

References

• Niesvizky R., Siegel D., Michaeli J. Biology and treatment of multiple myeloma. Blood Rev. 1993; 7: 24–33
   PubMed Web of Science ®Google Scholar
• Calabretta B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutical implications. Cancer Res. 1991; 51: 4505–4510
   PubMed Web of Science ®Google Scholar
• Carter G., Lemoine N. R. Antisense technology for cancer therapy: does it make sense?. Br. J. Cancer. 1993; 67: 869–876
   PubMed Web of Science ®Google Scholar
• Milligan J. F., Matteucci M. D., Martin J. C. Current concepts in antisense drug design. J. Med. Chem. 1993; 36: 1923–1937
   PubMed Web of Science ®Google Scholar
• Vaux D. L., Cory S., Adams J. M. Bcl-2 gene pro-motes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440–442
   PubMed Web of Science ®Google Scholar
• Hockenbery D., Nunez G., Milliman C., Schreiber R. D., Korsmayer S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334–336
   PubMed Web of Science ®Google Scholar
• Nunez G., London L., Hockenbery D., Alexander M., McKearn J. P., Korsmayer S. J. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J. Immunol. 1990; 144: 3602–3610
   PubMed Web of Science ®Google Scholar
• Reed J. C., Stein C., Subasinghe C., Haldar S., Croce C. M., Yum S., Cohen J. Antisense-mediated inhibition of bcl-2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 1990; 50: 6565–6570
   PubMed Web of Science ®Google Scholar
• Campos L., Sabido O., Rouault J.-P., Guyotat D. Effects of BCL-2 antisense olgodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994; 84: 595–600
   PubMed Web of Science ®Google Scholar
• Kitada S., Takayama S., De Riel K., Tanaka S., Reed J. C. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev. 1994; 4: 71–79
   PubMedGoogle Scholar
• Levy Y., Tsapis A., Brouet J.-C. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J. Clin. Invest. 1991; 88: 696–699
   PubMed Web of Science ®Google Scholar
• Schwab G., Siegall C. B., Aarden L. A., Neckers L. M., Nordan R. P. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 1991; 77: 587–593
   PubMed Web of Science ®Google Scholar
• Sburlati A. R., Manrow R. E., Berger S. L. Prothymosin a antisense oligomers inhibit myeloma cell division. Proc. Natl. Acad. Sci. USA. 1991; 88: 253–257
   PubMed Web of Science ®Google Scholar
• Jaroszewski J. W., Cohen J. S. Cellular uptake of antisense oligodeoxynucleotides. Adv. Drug Deliv. Rev. 1991; 6: 235–250
   Web of Science ®Google Scholar
• Wagner E., Zenke M., Cotten M., Beug H., Bimstiel M. L. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. USA. 1990; 87: 3410–3414
   PubMed Web of Science ®Google Scholar
• Clarenc J. P., Degols G., Leonetti J. P., Milhaud P., Lebleu B. Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation. Anticancer Drug Des. 1993; 8: 81–94
   PubMedGoogle Scholar
• Krieg A. M., Tonkinson J., Matson S., Zhao Q., Saxon M., Zhang L.-M., Bhanja U., Yakubov L., Stein C. A. Modification of antisense phosphodiester oligodeoxynucleotides by a 5′ cholesteryl moiety increases cellular association and improves efficacy. Proc. Natl. Acad. Sci. USA. 1993; 90: 1048–1052
   PubMed Web of Science ®Google Scholar
• Chow T. Y.-K., Juby C., Brousseau R. Specific targeting of antisense oligonucleotides to neutrophils. Antisense Res. Dev. 1994; 4: 81–86
   PubMedGoogle Scholar
• Akhtar S., Kole R., Juliano R. L. Stability of anti-sense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sciences 1991; 49: 1793–1801
   PubMed Web of Science ®Google Scholar
• Smith C. C., Aurelian L., Reddy M. P., Miller P. S., Ts'o P. O. P. Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type I immediate early pre-mRNAs 4 and 5. Proc. Nat!. Acad. Sci. USA. 1986; 83: 2787–2791
   PubMed Web of Science ®Google Scholar
• Gao W.-Y., Storm C., Egan W., Cheng Y.-C. Cellular pharmacology of phophorotioate homooligodeoxynucleotides in human cells. Mol. Pharmacol. 1993; 43: 45–50
   PubMed Web of Science ®Google Scholar
• Bennett C. F., Chiang M.-Y., Chan H., Shoemaker J. E. E., Mirabelli C. K. Cationic lipids enhance cellular uptake and activity of phosphorotioate antisense oligonucleotides. Mol. Pharmacol. 1992; 41: 1023–1033
   PubMed Web of Science ®Google Scholar
• Capaccioli S., Di Pasquale G., Mini E., Mazzei T., Quattrone A. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem. Biophys. Res. Commun. 1993; 197: 818–825
   PubMed Web of Science ®Google Scholar
• Lappalainen K., Urtti A., Söderling E., Jääskeläinen I., Syrjänen K., Syrjänen S. Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. Biochem. Biophys. Acta 1994; 1196: 201–208
   PubMed Web of Science ®Google Scholar
• Thierry A. R., Rahman A., Dritschilo A. Liposomal delivery as a new approach to transport antisense oligonucleotides. Gene Regulation: Biology of Antisense RNA and DNA, R. P. Erickson, J. G. Izantt. Raven Press, New York 1992; 147–161
   Google Scholar
• Temsamani J., Kebert M., Tang J., Padmapriya A., Agarawal S. Cellular uptake of oligodeoxynucleotide phosphorotioates and their analogs. Antisense Res. Dev. 1994; 4: 35–42
   PubMedGoogle Scholar
• Nilsson K., Bennich H., Johansson S. G. O., Ponten J. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 1970; 7: 477–489
   PubMed Web of Science ®Google Scholar
• Matsuoka Y., Moore G. E., Yagi Y., Pressman D. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc. Soc. Exp. Biol. Med. 1967; 125: 1246–1250
   PubMed Web of Science ®Google Scholar
• Goldblum R., Goldman A. S., Rudloff B., Harris N. S. (1973) An enhancing factor for in vitro growth of human plasma cells. Proceedings of the Seventh leucocytes culture conference. 1973, F. Dauillard. Academic Press, New York, 15–28
   Google Scholar
• Borset M., Helseth E., Naume B., Waage A. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br. J. Haemat. 1993; 85: 446–451
   PubMed Web of Science ®Google Scholar
• Rose J. K., Buonocore L., Whitt M. A. A new cationic liposome reagent mediating nearly quantitative transfection of animal cells. Biotechniques 1991; 10: 520–525
   PubMed Web of Science ®Google Scholar
• Jääskeläinen I., Mönkkönen J., Urtti A. Oligonucleotide-cationic liposome interactions. A physiochemical study. Biochem. Biophys. Acta 1994; 1195: 115–123
   PubMed Web of Science ®Google Scholar
• Haigler H. T., Maxfield F. R., Willingham M. C., Pastan I. Dansylcadaverine inhibits internalization of 123I-epidermal growth factor in BALB 3T3 cells. J. Biol. Chem. 1980; 255: 1239–1241
   PubMed Web of Science ®Google Scholar
• Gao W.-Y., Jarozewski J. W., Cohen J. S., Cheng Y. C. Mechanisms of inhibition of herpes simplex virus type 2 growth by 28-mer phophorotioate oligodeoxycytidine. J. Biol. Chem. 1990; 265: 20172–20178
   PubMed Web of Science ®Google Scholar
• Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform axtraction. Anal. Biochem. 1987; 162: 156–159
   PubMed Web of Science ®Google Scholar
• Lappalainen K., Urtti A., Jääskeläinen I., Syrjänen K., Syrjänen S. Cationic liposomes mediated delivery of antisense oligonucleotides targeted to HPV 16 mRNA in CaSki cells. Antiviral Res. 1994; 23: 119–130
   PubMed Web of Science ®Google Scholar
• Lappalainen K., Miettinen R., Kellokoski J., Jääskeläinen I., Syrjänen S. Uptake and intracellular distribution of liposomal oligonucleotides in CaSki cells at ultrastructural level, Submitted for publication
   Google Scholar
• Woolf T. M., Jennings C. G. B., Rebagliati M., Melton D. A. The stability, toxicity and effectiveness of unmodified and phosphorotioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos. Nucleic Acids Res. 1990; 18: 1763–1769
   PubMed Web of Science ®Google Scholar
• Cazenave C., Stein C. A., Loreau N., Thuong T., Neckers L. M., Subasinghe C., Helene C., Cohen S., Toulme J.-J. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. Nucleic Acids Res. 1989; 17: 4255–4273
   PubMed Web of Science ®Google Scholar
• Yaswen P., Stampfer M. R., Ghosh K., Cohen J. S. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res. Dev. 1993; 3: 67–77
   PubMedGoogle Scholar
• Reed J. C., Cuddy M., Haldar S., Croce C., Nowell P., Makover D., Bradley K. BCL2-mediated tumorigenicity of a human T-lymphoid cell line: Synergy with MYC and inhibition by BCL2 antisense. Proc. Natl. Acad. Sci. USA. 1990; 87: 3660–3664
   PubMed Web of Science ®Google Scholar
• Krieg A. M., Yi A.-K., Matson S., Waldschmidt T. J., Bishop G. A., Tesdale R., Koretzky G. A., Klinman D. M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546–549
   PubMed Web of Science ®Google Scholar
• Lappalainen K., Jääskeläinen I., Syrjänen K., Urtti A., Syrjänen S. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm. Res. 1994; 11: 1127–1131
   PubMed Web of Science ®Google Scholar